From MedTech Europe – please provide any comments to neil.plumridge@bivda.org.uk.
With this email, we would like to inform you about the latest chemical developments at ECHA and kindly ask you to indicate if any of the following impacts your company by 19 November.
Please note that the substances highlighted in yellow are the ones already present in the substance tracker – the latter is linked at the bottom of this email.
CLP
- Intention and proposal to harmonise classification and labelling – link here:
- Intention submitted for N-methylaniline* (EC 202-870-9, CAS 100-61-8).
- Proposal submitted for paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol (EC -, CAS 76738-62-0).
- Consultation on harmonised classification and labelling. Feedback period: 10/11/2025 – 9/01/2026 – link here:
- 2,4,6-tris(dimethylaminomethyl)phenol (EC 202-013-9, CAS 90-72-2).
REACH
ECHA published a screening report to assess whether the use of reaction products of 1,3,4-thiadiazolidine-2,5-dithione, formaldehyde and 4-heptylphenol, branched and linear (RP-HP) in articles should be restricted in accordance with REACH Article 69(2). ECHA recommends that any action on RP-HP substances in articles should be considered as part of the broader hydrocarbylphenols case (entry 1.4 of Annex II of the Restriction Roadmap).
Biocides
ECHA updated:
- The list of substances and product-type combinations that can be used in treated articles – link here.
- Article 95 list of active substance and product suppliers – link here.
- The list of substance and product-type combinations for which a compliant notification for inclusion in the Review Programme has been made – link here.
